---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115767"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:32:41.754050+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# enGene announces executive changes: new CTO, CSO, and President; Sullivan separation

## Summary
- Joan Connolly appointed CTO effective Oct 21; brings 30+ yrs experience from Albireo, Stemline, Bristol-Myers.
- Anthony Cheung transitions from CTO to CSO; James Sullivan departs Oct 31, 2024.
- Sullivan separation agreement includes $485k salary continuation, prorated bonus, equity acceleration, option extension.
- Alexander Nichols becomes Chief Strategy & Operations Officer; CEO Ron Cooper adds President title.
- Detalimogene pivotal study ongoing; enGene expects BLA submission mid-2026.

## SEC filing metadata
- accession: 0000950170-24-115767
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/engn-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115767
- JSON: https://secwatch.observer/filing/0000950170-24-115767.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115767.txt

## Key facts
- Executive change
  Anthony Cheung was appointed as Chief Scientific Officer at enGene Therapeutics Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: Dr. Anthony Cheung’s title and role changed from Chief Technology Officer to Chief Scientific Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm
- Executive change
  Ronald H.W. Cooper changed role as President at enGene Therapeutics Inc..
  - Action: assumed additional title of President
  - Role: President
  source text: Mr. Ronald H.W. Cooper, assumed the additional title of President
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm
- Executive change
  James Sullivan departed as Chief Scientific Officer at enGene Therapeutics Inc..
  - Action: depart
  - Role: Chief Scientific Officer
  source text: Dr. Sullivan shall depart the Company effective October 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm
- Executive change
  Alexander Nichols was appointed as Chief Strategy and Operations Officer at enGene Therapeutics Inc..
  - Action: appointed
  - Role: Chief Strategy and Operations Officer
  source text: Dr. Alexander Nichols’ title and role changed from President and Chief Operating Officer to Chief Strategy and Operations Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.